Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Set Alert for Brexit

US Pharma Firms Not In Post-Brexit Trade Talks

A UK TV program revealed secret meetings between drug makers and British civil servants but for its part, the American Pharmaceutical Group says it has had no discussions on any future US/UK trade deal.
United Kingdom Reimbursement Companies

Podcast: Novartis’s $9.7bn Gamble; Higher Drug Prices Post-Brexit? Jefferies Highlights

Join the London-based Eleanor Malone, Andrew McConaghie and Kevin Grogan as they review some of the most eyecatching stories in pharma and healthcare.

Europe Brexit BioPharmaceutical

Latest From Brexit

Scotland Wants NHS Protected From Post-Brexit Trade Deals

The Scottish National Party has put the NHS, EU membership and Scottish independence at the heart of its campaign as the UK prepares to vote in the 12 December general election.

United Kingdom Healthcare Systems

UK Conservatives Promise ‘Innovative Medicines Fund’ If Re-Elected

More money to pay for innovative new medicines, more cash and support for the life sciences sector, and Brexit by 31 January 2020 are among promises made in the Conservative Party’s election platform. 

United Kingdom Brexit

UK Labour Govt Would Boost Health Spending, Put Pressure On Drug Prices

The election manifesto produced by the Labour Party offers something for everyone, from the dropping of prescription charges and a boost for health care spending to more use of compulsory licensing and the building of a state-owned generics factory to make medicines more affordable.

United Kingdom Government Payers

Latest Notified Body Approval Helps Brexit-Proof EU Medical Devices Regulation

As the implementation deadline for the EU Medical Devices Regulation looms, the seventh notified body to be designated – BSI Netherlands – may hold the key to Brexit-proofing the new system. 
Health OTC Drugs

EMA Gets Keys To New HQ And Restarts Some Stalled Activities

The European Medicines Agency has taken possession of its new HQ in Amsterdam and has hired 77 new staff members to make up for the severe staff losses it has witnessed on account of Brexit. 

Europe Brexit

Pharma Declares Wishlist As Brexit Heightens UK Election Stakes

The UK pharma industry association has underscored the sector’s importance while outlining its demands for the country’s policy around medicines and R&D.

United Kingdom Brexit

UK BIA Targets Next Government With ‘Biotech Manifesto’

The BioIndustry Association has laid out its wishlist for the next UK administration, including deep regulatory alignment with the EU after Brexit, a more “flexible” approach to health technology assessment appraisals of new drugs, and support for R&D.

United Kingdom Brexit

UK Industry Hit By Brexit Uncertainty, Spies Opportunity

While post-Brexit regulatory alignment remains a priority for the British self-care industry, the increased flexibility afforded by the MHRA becoming a sovereign regulator could allow the UK to become a beacon of innovation on the edge of a re-aligned Europe, says PAGB CEO John Smith.
Health OTC Drugs

BSI Netherlands Designated Against EU MDR In Vital Move That Should Brexit-Proof Clients

BSI Netherlands is the seventh notified body to be designated under the EU’s Medical Device Regulation. But this latest announcement is one of the most important yet.

Europe EU
See All